Methods for determining cost-benefit ratios for pharmaceuticals in Germany
Schulenburg J-MG v. d., Vauth C, Mittendorf T, Greiner W (2007)
EUROPEAN JOURNAL OF HEALTH ECONOMICS 8(S1): 5-31.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Schulenburg, J. -Matthias Graf v. d.;
Vauth, Christoph;
Mittendorf, Thomas;
Greiner, WolfgangUniBi
Einrichtung
Abstract / Bemerkung
The aim of this methodological paper is to summarize evidence on how to implement cost-benefit assessment according to the new German legislative framework (Competition Enhancement Act). Given the complexity of existing health policy frameworks within industrialised countries in adapting health economics in their respective regulatory scheme, no clear international scientific consensus on which health economic methods should be chosen for assessment can be determined. Nevertheless, a broad consensus on the internal properties of methods itself can be found. Based on these common international standards in methodology, this work provides a minimum catalogue of methods and criteria that meet legal and local German requirements with regard to specific factors of its health care system. Aside from categorising clearly defined standards (e.g., study forms, cost and benefit categories) the suggested catalogue specifies some intensively debated areas in Germany (e.g., the QALY, modelling, the perspective used in the assessment). After the proposition of certain methods the paper leads to a first recommendation of a detailed assessment-process itself specific for the German way in implementing cost-benefit ratios within regulatory decision making in Germany.
Erscheinungsjahr
2007
Zeitschriftentitel
EUROPEAN JOURNAL OF HEALTH ECONOMICS
Band
8
Ausgabe
S1
Seite(n)
5-31
ISSN
1618-7598
eISSN
1618-7601
Page URI
https://pub.uni-bielefeld.de/record/1592386
Zitieren
Schulenburg J-MG v. d., Vauth C, Mittendorf T, Greiner W. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(S1):5-31.
Schulenburg, J. - M. G. v. d., Vauth, C., Mittendorf, T., & Greiner, W. (2007). Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 8(S1), 5-31. https://doi.org/10.1007/s10198-007-0063-4
Schulenburg, J. -Matthias Graf v. d., Vauth, Christoph, Mittendorf, Thomas, and Greiner, Wolfgang. 2007. “Methods for determining cost-benefit ratios for pharmaceuticals in Germany”. EUROPEAN JOURNAL OF HEALTH ECONOMICS 8 (S1): 5-31.
Schulenburg, J. - M. G. v. d., Vauth, C., Mittendorf, T., and Greiner, W. (2007). Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS 8, 5-31.
Schulenburg, J.-M.G. v. d., et al., 2007. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 8(S1), p 5-31.
J.-M.G. v. d. Schulenburg, et al., “Methods for determining cost-benefit ratios for pharmaceuticals in Germany”, EUROPEAN JOURNAL OF HEALTH ECONOMICS, vol. 8, 2007, pp. 5-31.
Schulenburg, J.-M.G. v. d., Vauth, C., Mittendorf, T., Greiner, W.: Methods for determining cost-benefit ratios for pharmaceuticals in Germany. EUROPEAN JOURNAL OF HEALTH ECONOMICS. 8, 5-31 (2007).
Schulenburg, J. -Matthias Graf v. d., Vauth, Christoph, Mittendorf, Thomas, and Greiner, Wolfgang. “Methods for determining cost-benefit ratios for pharmaceuticals in Germany”. EUROPEAN JOURNAL OF HEALTH ECONOMICS 8.S1 (2007): 5-31.
Daten bereitgestellt von European Bioinformatics Institute (EBI)
6 Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
Angelis A, Lange A, Kanavos P., Eur J Health Econ 19(1), 2018
PMID: 28303438
Angelis A, Lange A, Kanavos P., Eur J Health Econ 19(1), 2018
PMID: 28303438
Health technology assessment: research trends and future priorities in Europe.
Nielsen CP, Funch TM, Kristensen FB., J Health Serv Res Policy 16 Suppl 2(), 2011
PMID: 21737525
Nielsen CP, Funch TM, Kristensen FB., J Health Serv Res Policy 16 Suppl 2(), 2011
PMID: 21737525
Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.
Stafinski T, Menon D, Davis C, McCabe C., Clinicoecon Outcomes Res 3(), 2011
PMID: 22046102
Stafinski T, Menon D, Davis C, McCabe C., Clinicoecon Outcomes Res 3(), 2011
PMID: 22046102
[Modeling in value-based medicine].
Neubauer AS, Hirneiss C, Kampik A., Ophthalmologe 107(3), 2010
PMID: 20195613
Neubauer AS, Hirneiss C, Kampik A., Ophthalmologe 107(3), 2010
PMID: 20195613
Methods of economic evaluation for the German Statutory Healthcare System.
Dong H., Pharmacoeconomics 27(1), 2009
PMID: 19178119
Dong H., Pharmacoeconomics 27(1), 2009
PMID: 19178119
Methods of economic evaluation for the German statutory healthcare system.
Mittendorf T, Greiner W, von der Schulenburg JM., Pharmacoeconomics 27(3), 2009
PMID: 19354346
Mittendorf T, Greiner W, von der Schulenburg JM., Pharmacoeconomics 27(3), 2009
PMID: 19354346
70 References
Daten bereitgestellt von Europe PubMed Central.
Akehurst, Pharmacoeconomics 17(), 2000
Cost-of-illness studies : a review of current methods.
Akobundu E, Ju J, Blatt L, Mullins CD., Pharmacoeconomics 24(9), 2006
PMID: 16942122
Akobundu E, Ju J, Blatt L, Mullins CD., Pharmacoeconomics 24(9), 2006
PMID: 16942122
Disability-adjusted life years: a critical review.
Anand S, Hanson K., J Health Econ 16(6), 1997
PMID: 10176779
Anand S, Hanson K., J Health Econ 16(6), 1997
PMID: 10176779
The value of DALY life: problems with ethics and validity of disability adjusted life years.
Arnesen T, Nord E., Lepr Rev 71(2), 2000
PMID: 10920608
Arnesen T, Nord E., Lepr Rev 71(2), 2000
PMID: 10920608
Opening the debate on DALYs (disability-adjusted life years).
Barker C, Green A., Health Policy Plan 11(2), 1996
PMID: 10172660
Barker C, Green A., Health Policy Plan 11(2), 1996
PMID: 10172660
Modelling in the economic evaluation of health care: selecting the appropriate approach.
Barton P, Bryan S, Robinson S., J Health Serv Res Policy 9(2), 2004
PMID: 15099459
Barton P, Bryan S, Robinson S., J Health Serv Res Policy 9(2), 2004
PMID: 15099459
Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D.
Brazier JE, Kolotkin RL, Crosby RD, Williams GR., Value Health 7(4), 2004
PMID: 15449641
Brazier JE, Kolotkin RL, Crosby RD, Williams GR., Value Health 7(4), 2004
PMID: 15449641
The importance of patient-reported outcomes...it's all about the patients.
Bren L., FDA Consum 40(6), 2006
PMID: 17333563
Bren L., FDA Consum 40(6), 2006
PMID: 17333563
Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty.
Briggs A., Value Health 8(1), 2005
PMID: 15841888
Briggs A., Value Health 8(1), 2005
PMID: 15841888
An introduction to Markov modelling for economic evaluation.
Briggs A, Sculpher M., Pharmacoeconomics 13(4), 1998
PMID: 10178664
Briggs A, Sculpher M., Pharmacoeconomics 13(4), 1998
PMID: 10178664
The use of probabilistic decision models in technology assessment : the case of total hip replacement.
Briggs A, Sculpher M, Dawson J, Fitzpatrick R, Murray D, Malchau H., Appl Health Econ Health Policy 3(2), 2004
PMID: 15702945
Briggs A, Sculpher M, Dawson J, Fitzpatrick R, Murray D, Malchau H., Appl Health Econ Health Policy 3(2), 2004
PMID: 15702945
Statistical approaches to handling uncertainty in health economic evaluation.
Briggs AH., Eur J Gastroenterol Hepatol 16(6), 2004
PMID: 15167156
Briggs AH., Eur J Gastroenterol Hepatol 16(6), 2004
PMID: 15167156
Handling uncertainty in economic evaluations of healthcare interventions.
Briggs AH, Gray AM., BMJ 319(7210), 1999
PMID: 10473486
Briggs AH, Gray AM., BMJ 319(7210), 1999
PMID: 10473486
The death of cost-minimization analysis?
Briggs AH, O'Brien BJ., Health Econ 10(2), 2001
PMID: 11252048
Briggs AH, O'Brien BJ., Health Econ 10(2), 2001
PMID: 11252048
AUTHOR UNKNOWN, 0
The friction-cost method : replacement for nothing and leisure for free?
Brouwer WB, Koopmanschap MA., Pharmacoeconomics 23(2), 2005
PMID: 15748085
Brouwer WB, Koopmanschap MA., Pharmacoeconomics 23(2), 2005
PMID: 15748085
Need for differential discounting of costs and health effects in cost effectiveness analyses.
Brouwer WB, Niessen LW, Postma MJ, Rutten FF., BMJ 331(7514), 2005
PMID: 16110075
Brouwer WB, Niessen LW, Postma MJ, Rutten FF., BMJ 331(7514), 2005
PMID: 16110075
AUTHOR UNKNOWN, 0
A dollar is a dollar is a dollar--or is it?
Brouwer WB, van Exel NJ, Baltussen RM, Rutten FF., Value Health 9(5), 2006
PMID: 16961552
Brouwer WB, van Exel NJ, Baltussen RM, Rutten FF., Value Health 9(5), 2006
PMID: 16961552
Modelling in economic evaluation: an unavoidable fact of life.
Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M., Health Econ 6(3), 1997
PMID: 9226140
Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M., Health Econ 6(3), 1997
PMID: 9226140
Economic note: cost of illness studies.
Byford S, Torgerson DJ, Raftery J., BMJ 320(7245), 2000
PMID: 10807635
Byford S, Torgerson DJ, Raftery J., BMJ 320(7245), 2000
PMID: 10807635
Pharmacoeconomic analyses using discrete event simulation.
Caro JJ., Pharmacoeconomics 23(4), 2005
PMID: 15853433
Caro JJ., Pharmacoeconomics 23(4), 2005
PMID: 15853433
AUTHOR UNKNOWN, 0
The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies.
Claxton K., J Health Econ 18(3), 1999
PMID: 10537899
Claxton K., J Health Econ 18(3), 1999
PMID: 10537899
A rational framework for decision making by the National Institute For Clinical Excellence (NICE).
Claxton K, Sculpher M, Drummond M., Lancet 360(9334), 2002
PMID: 12241891
Claxton K, Sculpher M, Drummond M., Lancet 360(9334), 2002
PMID: 12241891
Interdisciplinary epidemiologic and economic research needed to support a universal childhood influenza vaccination policy.
Coleman MS, Washington ML, Orenstein WA, Gazmararian JA, Prill MM., Epidemiol Rev 28(), 2006
PMID: 16740584
Coleman MS, Washington ML, Orenstein WA, Gazmararian JA, Prill MM., Epidemiol Rev 28(), 2006
PMID: 16740584
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
Health economic guidelines--similarities, differences and some implications.
Hjelmgren J, Berggren F, Andersson F., Value Health 4(3), 2001
PMID: 11705185
Hjelmgren J, Berggren F, Andersson F., Value Health 4(3), 2001
PMID: 11705185
Hoffmann, Eur. J. Health Econ. 1(), 2000
The measurement of indirect costs in the health economics evaluation literature. A review.
Jacobs P, Fassbender K., Int J Technol Assess Health Care 14(4), 1998
PMID: 9885468
Jacobs P, Fassbender K., Int J Technol Assess Health Care 14(4), 1998
PMID: 9885468
Assessing the costs of healthcare technologies in clinical trials.
Johnston K, Buxton MJ, Jones DR, Fitzpatrick R., Health Technol Assess 3(6), 1999
PMID: 10350450
Johnston K, Buxton MJ, Jones DR, Fitzpatrick R., Health Technol Assess 3(6), 1999
PMID: 10350450
Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb.
Jonsson B, Weinstein MC., Int J Technol Assess Health Care 13(1), 1997
PMID: 9119623
Jonsson B, Weinstein MC., Int J Technol Assess Health Care 13(1), 1997
PMID: 9119623
The decision rules of cost-effectiveness analysis.
Karlsson G, Johannesson M., Pharmacoeconomics 9(2), 1996
PMID: 10160090
Karlsson G, Johannesson M., Pharmacoeconomics 9(2), 1996
PMID: 10160090
Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.
Karnon J., Health Econ 12(10), 2003
PMID: 14508868
Karnon J., Health Econ 12(10), 2003
PMID: 14508868
Kobelt, Gesund. Ökon. Qual. Manag. 10(), 2005
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO 3rd, Hughes M, Altman D, Buyse M, Galbraith S, Wells G., J. Rheumatol. 34(3), 2007
PMID: 17343307
Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO 3rd, Hughes M, Altman D, Buyse M, Galbraith S, Wells G., J. Rheumatol. 34(3), 2007
PMID: 17343307
Burden of illness.
McGuire T, Wells KB, Bruce ML, Miranda J, Scheffler R, Durham M, Ford DE, Lewis L; NIMH Affective Disorders Workgroup., Ment Health Serv Res 4(4), 2002
PMID: 12558002
McGuire T, Wells KB, Bruce ML, Miranda J, Scheffler R, Durham M, Ford DE, Lewis L; NIMH Affective Disorders Workgroup., Ment Health Serv Res 4(4), 2002
PMID: 12558002
Quantifying the burden of disease: the technical basis for disability-adjusted life years.
Murray CJ., Bull. World Health Organ. 72(3), 1994
PMID: 8062401
Murray CJ., Bull. World Health Organ. 72(3), 1994
PMID: 8062401
Understanding DALYs (disability-adjusted life years).
Murray CJ, Acharya AK., J Health Econ 16(6), 1997
PMID: 10176780
Murray CJ, Acharya AK., J Health Econ 16(6), 1997
PMID: 10176780
AUTHOR UNKNOWN, 0
An alternative to QALYs: the saved young life equivalent (SAVE)
Nord E., BMJ 305(6858), 1992
PMID: 1301030
Nord E., BMJ 305(6858), 1992
PMID: 1301030
[Quality adjustment of life years--possibilities, limitations, alternatives]
Nord E., Tidsskr. Nor. Laegeforen. 112(20), 1992
PMID: 1412294
Nord E., Tidsskr. Nor. Laegeforen. 112(20), 1992
PMID: 1412294
Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.
Philips Z, Bojke L, Sculpher M, Claxton K, Golder S., Pharmacoeconomics 24(4), 2006
PMID: 16605282
Philips Z, Bojke L, Sculpher M, Claxton K, Golder S., Pharmacoeconomics 24(4), 2006
PMID: 16605282
AUTHOR UNKNOWN, 0
Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review.
Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R., Int J Technol Assess Health Care 22(2), 2006
PMID: 16571199
Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R., Int J Technol Assess Health Care 22(2), 2006
PMID: 16571199
Ravens-Sieberer, 2000
Rohrbacher, Gesund. Ökon. Qual. Manag. 10(), 2005
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
Whither trial-based economic evaluation for health care decision making?
Sculpher MJ, Claxton K, Drummond M, McCabe C., Health Econ 15(7), 2006
PMID: 16491461
Sculpher MJ, Claxton K, Drummond M, McCabe C., Health Econ 15(7), 2006
PMID: 16491461
AUTHOR UNKNOWN, 0
Using the Delphi technique in economic evaluation: time to revisit the oracle?
Simoens S., J Clin Pharm Ther 31(6), 2006
PMID: 17176357
Simoens S., J Clin Pharm Ther 31(6), 2006
PMID: 17176357
The lag between effectiveness and cost-effectiveness evidence of new drugs. Implications for decision-making in health care.
Stoykova B, Drummond M, Barbieri M, Kleijnen J., Eur J Health Econ 4(4), 2003
PMID: 15609202
Stoykova B, Drummond M, Barbieri M, Kleijnen J., Eur J Health Econ 4(4), 2003
PMID: 15609202
Tarn, ISPOR Connections 10(), 2004
Developing guidance for budget impact analysis.
Trueman P, Drummond M, Hutton J., Pharmacoeconomics 19(6), 2001
PMID: 11456210
Trueman P, Drummond M, Hutton J., Pharmacoeconomics 19(6), 2001
PMID: 11456210
US, Health Qual. Life Outcomes 4(), 2006
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices--Modeling Studies., Value Health 6(1), 2003
PMID: 12535234
Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices--Modeling Studies., Value Health 6(1), 2003
PMID: 12535234
Statistical evaluation of biomarkers as surrogate endpoints: a literature review.
Weir CJ, Walley RJ., Stat Med 25(2), 2006
PMID: 16252272
Weir CJ, Walley RJ., Stat Med 25(2), 2006
PMID: 16252272
A decision chart for assessing and improving the transferability of economic evaluation results between countries.
Welte R, Feenstra T, Jager H, Leidl R., Pharmacoeconomics 22(13), 2004
PMID: 15329031
Welte R, Feenstra T, Jager H, Leidl R., Pharmacoeconomics 22(13), 2004
PMID: 15329031
Zentner, GMS Health Technol. Assess. Doc. 09(), 2005
Zentner, Gesundh. Ökon. Qual. Manag. 11(), 2006
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 17582539
PubMed | Europe PMC
Suchen in